The latest price target for Cardiol Therapeutics (NASDAQ:CRDL) was reported by Canaccord Genuity on April 6, 2026. The analyst firm set a price target for $8.00 expecting CRDL to rise to within 12 months (a possible 433.33% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Cardiol Therapeutics (NASDAQ:CRDL) was provided by Canaccord Genuity, and Cardiol Therapeutics maintained their buy rating.

There is no last upgrade for Cardiol Therapeutics

There is no last downgrade for Cardiol Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cardiol Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cardiol Therapeutics was filed on April 6, 2026 so you should expect the next rating to be made available sometime around April 6, 2027.

While ratings are subjective and will change, the latest Cardiol Therapeutics (CRDL) rating was a maintained with a price target of $8.00 to $8.00. The current price Cardiol Therapeutics (CRDL) is trading at is $1.50, which is out of the analyst’s predicted range.